Advertisement
Organisation › Details
Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. *
Start | 1941-01-01 established | |
Group | Eisai (Group) | |
Industry | pharmaceutical | |
Region | Tokyo | |
Country | Japan | |
Street | 4-6-10 Koishikawa, Bunkyo-ku | |
City | n. a. Tokyo 112-88 | |
Tel | 03-3817-5120 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | G: 5,001 to 10,000 (2019-09-20) |
* Document for »About Section«: Newron Pharmaceuticals S.p.A.. (9/20/19). "Press Release: Newron Pharmaceutical Commercialization Partner Meiji Seika together with Eisai Announce the Approval of Safinamide for Parkinson’s Disease in Japan". Milan. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Eisai (Group)
- [1] Numab Therapeutics AG. (10/1/19). "Press Release: Numab and Eisai Enter into a Global Research and Option Agreement to Discover and Develop Multi-specific Antibody Immunotherapies for Cancer". Tokyo & Zurich....
- [2] CureVac AG. (1/28/19). "Press Release: CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer". Tübingen & Boston, MA....
- [3] Calypso Biotech S.A.. (3/31/17). "Press Release: Calypso Biotech Licenses CALY-001 Best-in-Class Anti-MMP-9 Antibody to EA Pharma". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top